SJOGRENS-SYNDROME MIMICKING MULTIPLE-SCLEROSIS - REPLY

SJOGRENS-SYNDROME MIMICKING MULTIPLE-SCLEROSIS - REPLY

Bibliográfalaš dieđut
Váldodahkkit:	Noseworthy, J, Bass, B, Vandervoort, M, Ebers, G, Rice, G, Weinshenker, B, Mclay, C, Bell, D
Materiálatiipa:	Journal article
Almmustuhtton:	1990

Geahča maid

The prevalence of primary Sjogren's syndrome in a multiple sclerosis population.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1989)

FAILURE TO FIND PATIENTS WITH NERVOUS-SYSTEM MANIFESTATIONS OF PRIMARY SJOGRENS SYNDROME IN A MULTIPLE-SCLEROSIS CLINIC POPULATION
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1988)

TIZANIDINE VERSUS BACLOFEN IN THE TREATMENT OF SPASTICITY IN PATIENTS WITH MULTIPLE-SCLEROSIS - A DOUBLE-BLIND-STUDY
Dahkki: Bass, B, et al.
Almmustuhtton: (1987)

THE NATURAL-HISTORY OF MULTIPLE-SCLEROSIS - A GEOGRAPHICALLY BASED STUDY
Dahkki: Weinshenker, B, et al.
Almmustuhtton: (1989)

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
Dahkki: Bass, B, et al.
Almmustuhtton: (1988)

An open trial of OKT3 in patients with multiple sclerosis.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1991)

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1989)

Acceptance of placebo-control trial design by progressive multiple sclerosis patients. The Canadian Cooperative Multiple Sclerosis Study Group.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1989)

A PRELIMINARY CLINICAL-TRIAL OF ORTHOCLONE OKT-STAR-3 TREATMENT IN CHRONICALLY PROGRESSIVE MULTIPLE-SCLEROSIS
Dahkki: Weinshenker, B, et al.
Almmustuhtton: (1988)

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1989)

ACCEPTANCE OF PLACEBO-CONTROL TRIAL DESIGN BY PROGRESSIVE MULTIPLE-SCLEROSIS PATIENTS
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1989)

A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1992)

EDSS RELIABILITY - REPLY
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1991)

MS REFERENDUM - REPLY
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1990)

MULTIPLE-SCLEROSIS IN TWINS - REPLY
Dahkki: Ebers, G
Almmustuhtton: (1987)

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1989)

INTERRATER VARIABILITY WITH THE EXPANDED DISABILITY STATUS SCALE (EDSS) AND FUNCTIONAL-SYSTEMS (FS) IN A MULTIPLE-SCLEROSIS CLINICAL-TRIAL
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1990)

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1991)

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1991)

The natural history of multiple sclerosis.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1987)

PAIN IN MULTIPLE-SCLEROSIS - REPLY
Dahkki: Moulin, D, et al.
Almmustuhtton: (1989)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Systemic interferon alfa in multiple sclerosis.
Dahkki: Weinshenker, BG, et al.
Almmustuhtton: (1989)

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1990)

Hyperbaric oxygen therapy in chronic stable multiple sclerosis: double-blind study.
Dahkki: Harpur, G, et al.
Almmustuhtton: (1986)

Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis.
Dahkki: Wiebe, S, et al.
Almmustuhtton: (1992)

Interpretation of single band patterns in CSF protein electrophoresis.
Dahkki: Bass, B, et al.
Almmustuhtton: (1988)

SIGNIFICANCE OF THE SINGLE BAND IN CSF PROTEIN ELECTROPHORESIS
Dahkki: Bass, B, et al.
Almmustuhtton: (1986)

Neuroimaging in multiple sclerosis.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1984)

IDENTIFYING SUITABLE CANDIDATES FOR CLINICAL-TRIALS OF PROGRESSIVE MULTIPLE-SCLEROSIS
Dahkki: Weinshenker, B, et al.
Almmustuhtton: (1993)

ACTIVE RELAPSING AND PROGRESSIVE MULTIPLE-SCLEROSIS PATIENTS HAVE SIMILAR MAGNETIC-RESONANCE-IMAGING BEHAVIOR - IMPLICATIONS FOR CLINICAL-TRIAL DESIGN
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1990)

Primary biliary cirrhosis and multiple sclerosis.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1989)

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1994)

Therapeutic trials in multiple sclerosis.
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1984)

APPLICATIONS OF STUDIES OF THE NATURAL-HISTORY OF MULTIPLE-SCLEROSIS TO THE PLANNING AND INTERPRETATION OF CLINICAL-TRIALS
Dahkki: Weinshenker, B, et al.
Almmustuhtton: (1989)

MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS Reply
Dahkki: Ebers, G, et al.
Almmustuhtton: (2009)

MARKERS AND PROGNOSIS IN MULTIPLE-SCLEROSIS
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (1983)

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article]
Dahkki: Noseworthy, J, et al.
Almmustuhtton: (2001)

OLIGOCLONAL BANDS IN MULTIPLE-SCLEROSIS - AN INDEX OF DISEASE-ACTIVITY - REPLY
Dahkki: Ebers, G, et al.
Almmustuhtton: (1985)